NewAmsterdam Pharma (NAMS) Receivables - Other (2021 - 2026)

NewAmsterdam Pharma has disclosed Receivables - Other across 5 years of filings, most recently posting $8.0 million for Q1 2026.

• Receivables - Other for Q1 2026 came in at $8.0 million, up 455.83% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.0 million (up 455.83% YoY), and the FY2025 annual result was $6.8 million, up 287.01% from the prior year.
• Receivables - Other came in at $8.0 million for Q1 2026 at NewAmsterdam Pharma, up from $6.8 million in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $8.0 million in Q1 2026 to a low of $875000.0 in Q4 2023.
• The 4-year median for Receivables - Other is $2.7 million (2024), against an average of $3.4 million.
• Across the five-year window, Receivables - Other slumped 63.81% in 2025 and jumped 455.83% in 2026, its largest moves.
• NewAmsterdam Pharma's Receivables - Other stood at $875000.0 in 2023, then surged by 99.77% to $1.7 million in 2024, then surged by 287.01% to $6.8 million in 2025, then rose by 18.48% to $8.0 million in 2026.
• The last three Receivables - Other figures came in at $8.0 million (Q1 2026), $6.8 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.